PD482 - CZECH HOME PARENTERAL NUTRITION REGISTRY: THE UPDATED DATA ON PREVALENCE, INCIDENCE, DIAGNOSES, SYNDROMES, PERFORMANCE, WEANING, AND COMPLICATIONS

PD482

CZECH HOME PARENTERAL NUTRITION REGISTRY: THE UPDATED DATA ON PREVALENCE, INCIDENCE, DIAGNOSES, SYNDROMES, PERFORMANCE, WEANING, AND COMPLICATIONS

P. Tesinsky^1,*, P. Wohl², P. Benes³, A. Ouradova¹, J. Gojda¹ on behalf of Czech Home Parenteral Nutrition Working Grpoup on behalf of Czech Home Parenteral Nutrition Working Group

¹Nutrition Center, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University, ²Dept. of Diabetology and Nutrition Center, Institute for Clinical and Experimental Medicine, ³Dept. of Medicine, Nutrition Center, Faculty Hospital Motol and Homolka, Prague, Czech Republic

Rationale: Statistically processed analysis of data of HPN patients based on reports from HPN centres in Czechia.

Methods: Prospectively collected data using a standardised online form and analysed by competing-risks regression model or presented as median or mean (CI 95%).

Results: Ttotal number of patients in the Registry is 2324: adults 2214 (95.3%), paediatric 110 (4.7%). Number of  visits is 5454/year. Incidence rate of HPN is 1.98. Lifetime dependency is expected in 20.9%, 24.2% patients are palliative. SBS was present in 787 patients (36.9%), intestinal obstruction in 565 (24.3%), and malabsorption in 328 (13.8%). Dominant indications for HPN were malignancies (45.5%), non-malignant surgical conditions (13.1%), Crohn disease (11.5%), and mesenteric occlusion (6.7%). Mobility was reported from 77.8%, economic activity from 323 (28.2 %) out of 1142 economically potent patients. A tunnelled catheter was used in 46.9%, PICC in 27.1%, and IV port in 16.9% patients. Premixed bags were used in 69.1%, and pharmacy-prepared admixtures in 25.7%. 63.0% patients were administered one bag/day, 7 days a week. Sepsis rate per 1000 catheter days decreased from 0.84 in 2013 to 0.17 in 2024, catheter occlusion rate from 0.15 to 0.07, and thrombotic complications from 0.16 to 0.04. Bone disease is present in 15.9 % patients, fibrosis in 22.3%, and steatosis in 47.6%. In 12 months, 28 % patients achieve intestinal autonomy, increasing to 45 % after 5 years. Survival rate is 62% in the first year, 45% after 5, and 35% after 10 years. Tedeglutide was inidicated 39 patients (30 adults, 9 paediatric) with reduction of the daily volume to 60.3% on average.

Conclusion: Prevalence of HPN is increasing, namely in the palliative group. Majority of patients is expected to terminate HPN within the first year. Rate of CRS decreased significantly. Tedeglutide significantly reduced IV needs.

Disclosure of Interest: P. Tesinsky Grant / Research Support from: Takeda, P. Wohl Grant / Research Support from: Takeda, P. Benes Grant / Research Support from: Takeda, A. Ouradova Grant / Research Support from: Takeda, J. Gojda Grant / Research Support from: Takeda